← Back to Search

Botulinum Toxin

AGN-151586 for Frown Lines

Phase 3
Waitlist Available
Research Sponsored by Allergan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be able to accurately assess their facial lines without the use of eyeglasses (contact lens use is acceptable).
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 126
Awards & highlights

Study Summary

This trial is testing the safety of AGN-151586, an investigational product being developed for the treatment of glabellar lines (GL). 880 adult participants with moderate to severe GL will receive 5 intramuscular AGN-151586 injections on Day 1, and may receive up to 2 additional cycles of treatment during the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You need to be able to see your facial lines clearly without wearing glasses (contact lenses are okay).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 126
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to day 126 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Electrocardiogram (ECG) Measurements
Change in Vital Sign Measurements
Number of Participants with Adverse Events
+1 more

Side effects data

From 2020 Phase 2 trial • 198 Patients • NCT04096326
26%
Injection site pain
7%
Dysgeusia
4%
Nausea
4%
Headache
4%
Dizziness
4%
Paronychia
4%
Urinary tract infection
4%
Urticaria
4%
Muscle strain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort 3: AGN-151586
Cohort 2: AGN-151586
Cohort 1: AGN-151586
Cohort 1: Placebo
Cohort 5: Placebo
Cohort 2: Placebo
Cohort 3: Placebo
Cohort 4: Placebo
Cohort 4: AGN-151586
Cohort 5: AGN-151586

Trial Design

1Treatment groups
Experimental Treatment
Group I: AGN-151586Experimental Treatment1 Intervention
Participants will receive 5 intramuscular injections in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may receive up to 2 additional cycles of open-label treatments.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AGN-151586
2022
Completed Phase 3
~2230

Find a Location

Who is running the clinical trial?

AllerganLead Sponsor
781 Previous Clinical Trials
274,807 Total Patients Enrolled
1 Trials studying Frown Lines
101 Patients Enrolled for Frown Lines
ALLERGAN INC.Study DirectorAllergan
75 Previous Clinical Trials
77,497 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there risks involved with AGN-151586?

"AGN-151586 has been given a 3 for safety. This is based on the fact that it is a Phase 3 trial, so while there is some data to support efficacy, there are also multiple rounds of data to support safety."

Answered by AI

Are there other places in town where this research project is taking place?

"There are 43 clinical trial sites recruiting patients for this study, including the Northwest Dermatology Institute in Portland, Advanced Research Associates in Glendale, and Skin Research Institute LLC in Coral Gables."

Answered by AI

Who else is applying?

What state do they live in?
New Jersey
California
Texas
Other
How old are they?
18 - 65
What site did they apply to?
Skin Care and Laser Physicians of Beverly Hills /ID# 241237
Art of Skin MD /ID# 241244
DermResearch, Inc. Austin, TX /ID# 241228
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
3+

Why did patients apply to this trial?

I have tried creams that didn't work.
PatientReceived 2+ prior treatments
~320 spots leftby Mar 2025